Hs-crp-driven strategy
Hs-crp-driven strategy has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Nov 2, 2026: “Elevated High-Sensitivity C-Reactive Protein as a Prescribing Trigger versus a Risk-Enhancing Factor Identifies Distinct Primary Prevention Populations for Statin Therapy”.
1 paper studies it1 findingUpdated
1 new paper in 30 daysSee all 1 papers on hs-crp-driven strategy
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Using elevated hs-CRP as a standalone statin indication identified five times more patients”
- 1 lab in 1 country
- Humans1
What did studies of hs-crp-driven strategy find?
1Studies of hs-crp-driven strategy measured one outcome, eligibility for statin therapy.
Eligibility for statin therapy
upin humans1
1 study
Eligibility for statin therapy
upin humans1
Hs-crp-driven strategy is linked with higher eligibility for statin therapy in humans (473 (22%) versus 92 (4.3%) eligible).
“Using elevated hs-CRP as a standalone statin indication identified five times more patients”
HumansNo prior ASCVD and PREVENT 10-year ASCVD risk <5%; compared with the borderline-risk refinement strategyn = 2,149
AHA Scientific Sessions 2026 abstract